• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

泊洛沙姆-188佐剂通过抑制p38丝裂原活化蛋白激酶信号通路有效维持SARS-CoV-2刺突蛋白受体结合域亚单位疫苗的适应性免疫。

Poloxamer-188 Adjuvant Efficiently Maintains Adaptive Immunity of SARS-CoV-2 RBD Subunit Vaccination through Repressing p38MAPK Signaling.

作者信息

Chen Chao-Hung, Lin Yu-Jen, Cheng Li-Ting, Lin Chien-Hung, Ke Guan-Ming

机构信息

Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 10650, Taiwan.

General Research Service Center, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan.

出版信息

Vaccines (Basel). 2022 May 2;10(5):715. doi: 10.3390/vaccines10050715.

DOI:10.3390/vaccines10050715
PMID:35632471
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9145454/
Abstract

Poloxamer-188 (P188) is a nonionic triblock linear copolymer that can be used as a pharmaceutical excipient because of its amphiphilic nature. This study investigated whether P188 can act as an adjuvant to improve the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) subunit vaccine. BALB/c mice were vaccinated twice with the RBD antigen alone or in combination with P188 or MF59 (a commercial adjuvant for comparison purposes). The resulting humoral and cellular immunity were assessed. Results showed that P188 helped elicit higher neutralizing activity than MF59 after vaccination. P188 induced significant humoral immune response, along with type 1 T helper (Th1) and type 2 T helper (Th2) cellular immune response when compared with MF59 due to repressing p38MAPK phosphorylation. Furthermore, P188 did not result in adverse effects such as fibrosis of liver or kidney after vaccination. In conclusion, P188 is a novel adjuvant that may be used for safe and effective immune enhancement of the SARS-CoV-2 RBD antigen.

摘要

泊洛沙姆-188（P188）是一种非离子型三嵌段线性共聚物，因其具有两亲性，可作为药用辅料。本研究调查了P188是否可作为佐剂来提高严重急性呼吸综合征冠状病毒2（SARS-CoV-2）受体结合域（RBD）亚单位疫苗的免疫原性。将BALB/c小鼠分别单独接种RBD抗原，或与P188或MF59（一种用于比较的商业佐剂）联合接种两次。评估由此产生的体液免疫和细胞免疫。结果显示，接种疫苗后，P188比MF59诱导产生更高的中和活性。与MF59相比，P188诱导产生显著的体液免疫应答以及1型辅助性T细胞（Th1）和2型辅助性T细胞（Th2）细胞免疫应答，这是由于其抑制了p38丝裂原活化蛋白激酶（p38MAPK）的磷酸化。此外，接种疫苗后P188未导致如肝或肾纤维化等不良反应。总之，P188是一种新型佐剂，可用于安全有效地增强SARS-CoV-2 RBD抗原的免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/03e0eccfabad/vaccines-10-00715-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/eef83d520d34/vaccines-10-00715-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/15f45309b6a8/vaccines-10-00715-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/afb5573d3b3f/vaccines-10-00715-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/061a1a5ecd88/vaccines-10-00715-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/d0373069db98/vaccines-10-00715-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/374288dedd36/vaccines-10-00715-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/29d8e2ca2dc5/vaccines-10-00715-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/03e0eccfabad/vaccines-10-00715-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/eef83d520d34/vaccines-10-00715-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/15f45309b6a8/vaccines-10-00715-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/afb5573d3b3f/vaccines-10-00715-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/061a1a5ecd88/vaccines-10-00715-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/d0373069db98/vaccines-10-00715-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/374288dedd36/vaccines-10-00715-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/29d8e2ca2dc5/vaccines-10-00715-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aac/9145454/03e0eccfabad/vaccines-10-00715-g008.jpg

相似文献

1
Poloxamer-188 Adjuvant Efficiently Maintains Adaptive Immunity of SARS-CoV-2 RBD Subunit Vaccination through Repressing p38MAPK Signaling.泊洛沙姆-188佐剂通过抑制p38丝裂原活化蛋白激酶信号通路有效维持SARS-CoV-2刺突蛋白受体结合域亚单位疫苗的适应性免疫。
Vaccines (Basel). 2022 May 2;10(5):715. doi: 10.3390/vaccines10050715.
2
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
3
Recombinant Expressing SARS-CoV-2 Receptor-Binding Domain as a Vaccine Candidate Against SARS-CoV-2 Infections.表达严重急性呼吸综合征冠状病毒2受体结合域的重组体作为抗严重急性呼吸综合征冠状病毒2感染的候选疫苗。
Front Immunol. 2021 Aug 27;12:712274. doi: 10.3389/fimmu.2021.712274. eCollection 2021.
4
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.新型冠状病毒 ARCoV mRNA 疫苗在中国成年人中的安全性和免疫原性：一项随机、双盲、安慰剂对照、1 期临床试验。
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
5
An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.一种工程化受体结合域可提高多价SARS-CoV-2疫苗的免疫原性。
mBio. 2021 May 11;12(3):e00930-21. doi: 10.1128/mBio.00930-21.
6
A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.一种新型针对 SARS-CoV-2 的 DNA 疫苗，编码一种嵌合蛋白，由其受体结合域（RBD）与乙型肝炎病毒前 S1 区的氨基末端融合，该嵌合蛋白带有 W4P 突变。
Front Immunol. 2021 Feb 26;12:637654. doi: 10.3389/fimmu.2021.637654. eCollection 2021.
7
Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.针对中东呼吸综合征冠状病毒的基于受体结合域的亚单位疫苗的抗原剂量优化
Hum Vaccin Immunother. 2015;11(5):1244-50. doi: 10.1080/21645515.2015.1021527.
8
A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.一种靶向淋巴结的两亲体疫苗诱导针对 SARS-CoV-2 的强烈细胞和体液免疫。
Sci Adv. 2021 Feb 5;7(6). doi: 10.1126/sciadv.abe5819. Print 2021 Feb.
9
Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.mRNA 疫苗接种后针对 SARS-CoV-2 变体 RBD 的中和抗体反应减弱和异质性。
Front Immunol. 2022 Apr 6;13:816389. doi: 10.3389/fimmu.2022.816389. eCollection 2022.
10
Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in mice.口服酵母重组 SARS-CoV-2 疫苗诱导小鼠的免疫应答。
Microb Cell Fact. 2021 May 5;20(1):95. doi: 10.1186/s12934-021-01584-5.

引用本文的文献

1
Nanotechnology-Driven Strategy Against SARS-CoV-2: Pluronic F127-Based Nanomicelles with or Without Atazanavir Reduce Viral Replication in Calu-3 Cells.纳米技术驱动的抗SARS-CoV-2策略：含或不含阿扎那韦的基于普朗尼克F127的纳米胶束可减少Calu-3细胞中的病毒复制
Viruses. 2025 Apr 1;17(4):518. doi: 10.3390/v17040518.
2
Influence of Parameters Used to Prepare Sterile Solutions of Poloxamer 188 on Their Physicochemical Properties.制备泊洛沙姆188无菌溶液所用参数对其理化性质的影响。
Polymers (Basel). 2024 Dec 29;17(1):62. doi: 10.3390/polym17010062.
3
Poloxamers Have Vaccine-Adjuvant Properties by Increasing Dissemination of Particulate Antigen at Distant Lymph Nodes.

本文引用的文献

1
Antibodies for COVID-19 - which, when and how long?新冠病毒抗体检测：何时、如何以及多久检测一次？
J Biol Regul Homeost Agents. 2021 Mar-Apr;35(2):417-422. doi: 10.23812/Theo_edit.
2
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.一种用于新型冠状病毒2的MF59佐剂刺突糖蛋白钳夹疫苗的安全性和免疫原性：一项随机、双盲、安慰剂对照的1期试验。
Lancet Infect Dis. 2021 Oct;21(10):1383-1394. doi: 10.1016/S1473-3099(21)00200-0. Epub 2021 Apr 19.
3
Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
泊洛沙姆具有佐剂特性，可增加颗粒状抗原在远处淋巴结的传播。
Molecules. 2023 Jun 15;28(12):4778. doi: 10.3390/molecules28124778.
聚氧乙烯月桂醚 188 对比安慰剂对镰状细胞病儿童和成人血管阻塞性危象疼痛的影响：一项随机临床试验。
JAMA. 2021 Apr 20;325(15):1513-1523. doi: 10.1001/jama.2021.3414.
4
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.接种 ChAdOx1 nCov-19 疫苗后发生血栓性血小板减少症。
N Engl J Med. 2021 Jun 3;384(22):2092-2101. doi: 10.1056/NEJMoa2104840. Epub 2021 Apr 9.
5
Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2.针对中东呼吸综合征冠状病毒（MERS-CoV）和严重急性呼吸综合征冠状病毒2（SARS-CoV2）的人内源性逆转录病毒包膜杆状病毒DNA疫苗。
NPJ Vaccines. 2021 Mar 19;6(1):37. doi: 10.1038/s41541-021-00303-w.
6
Drug localization and its effect on the physical stability of poloxamer 188-stabilized colloidal lipid emulsions.药物定位及其对泊洛沙姆 188 稳定胶体脂质乳剂物理稳定性的影响。
Int J Pharm. 2021 Apr 15;599:120394. doi: 10.1016/j.ijpharm.2021.120394. Epub 2021 Mar 3.
7
The Peptide Vaccine of the Future.未来的肽疫苗。
Mol Cell Proteomics. 2021;20:100022. doi: 10.1074/mcp.R120.002309. Epub 2021 Feb 8.
8
COVID-19 vaccines: The status and perspectives in delivery points of view.COVID-19 疫苗：交付观点中的现状和展望。
Adv Drug Deliv Rev. 2021 Mar;170:1-25. doi: 10.1016/j.addr.2020.12.011. Epub 2020 Dec 24.
9
Non-viral COVID-19 vaccine delivery systems.非病毒 COVID-19 疫苗传递系统。
Adv Drug Deliv Rev. 2021 Feb;169:137-151. doi: 10.1016/j.addr.2020.12.008. Epub 2020 Dec 17.
10
ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease.ACE2 和 TMPRSS2 多态性与各种疾病的关系，特别是其对 COVID-19 疾病的影响。
Microb Pathog. 2021 Jan;150:104621. doi: 10.1016/j.micpath.2020.104621. Epub 2020 Dec 2.